tradmap

RXST Rxsight, Inc.

$4.80 -1.13%

Data as of close

Healthcare · Ophthalmic Goods

Rxsight, Inc. (RXST) is a healthcare company in the Ophthalmic Goods industry, with a market capitalization of $200 million. Shares last traded at $4.80, 64.4% below their 52-week high. Over the past year the stock is down 44.1%. Net profit margin is -38.8%, below the peer median of 1.0%. Revenue declined 3.9% year over year.

Market Cap
$200M
Shares Out
41.6M
EPS (TTM)
-$1.13
P/E (TTM)*
—
P/S Ratio
1.65
P/B Ratio
0.76
Dividend / Share
—
Dividend Yield
—
52-Week High
$13.50
52-Week Low
$4.40
Volume (venue)
123,137
Avg Vol (3m, venue)
54,106.778

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
-2.74%
1M
+2.35%
3M
-23.20%
6M
-34.96%
YTD
-53.98%
1Y
-44.06%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
44.53
SMA (50)
$5.36
SMA (200)
$6.33
Price vs SMA50
-10.52%
Price vs SMA200
-24.23%
ATR (14)
$0.25

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$121M
Net Income
-$47M
Gross Margin
76.3%
Operating Margin
-45.5%
Net Margin
-38.8%
Return on Equity
-17.8%
Return on Assets
-13.3%
Current Ratio
4.07
Debt / Equity
0.00
Revenue Growth (YoY)
-3.9%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 -$0.29 2026-08-05
Q1 2026 -$0.38 2026-05-06
Q4 2025 (derived) -$0.22 2026-02-25
FY 2025 -$0.95 2026-02-25
Q3 2025 -$0.24 2025-11-05
Q2 2025 -$0.29 2025-08-07

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Ophthalmic Goods peers

RXST vs 9 industry peers (Ophthalmic Goods), by market cap. Data as of close

P/S vs peers
1.65 / 2.20 med
-25% discount
Net margin vs peers
-38.8% / 1.0% med
below median
1–9 of 9
ALCAlcon Inc$35.9B———+2.97%
COOCooper Companies (The)$11.7B20.442.7513.5%+2.97%
BLCOBausch & Lomb Corp$7.2B—1.32-2.0%+0.18%
WRBYWarby Parker Inc.$2.9B380.793.230.8%-3.07%
EYENational Vision Holdings, Inc.$1.4B26.970.672.5%+3.38%
STAAStaar Surgical Co$1.3B325.823.681.1%+1.61%
RXSTRxsight, Inc.$200M—1.65-38.8%-1.13%
LUCYInnovative Eyewear Inc$7M———+1.33%
LUCYWInnovative Eyewear Inc————+3.93%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.